Literature DB >> 29369538

Long-term uveal melanoma survivors: measuring their quality of life.

Shahar Frenkel1, Hadas Rosenne2, Daniel Briscoe3, Karen Hendler1, Ronen Bereket1, Michal Molcho4, Jacob Pe'er1.   

Abstract

PURPOSE: Patients with uveal melanoma (UM) undergo lifelong follow-up as metastases can occur more than 20 years after diagnosis. Little is known about the quality of life (QoL) of UM survivors over such an extended period. To investigate their QoL, we used various estimating factors.
METHODS: A cohort of patients diagnosed and treated for UM with regularly scheduled follow-up visits was asked to fill in a European Organization for Research and Treatment of Cancer (EORTC) questionnaire comprised of the EORTC QLQ-C30 and EORTC QLQ-OPT30 modules. An additional open question examined other changes in the patients' lifestyle since diagnosis. Independent demographic and medical data were collected from patient records.
RESULTS: Two hundred and thirty-two of 294 patients agreed to complete the questionnaire. General QoL correlated highly with the eye-related QoL. Statistically significant higher QoL was associated with tumours not involving the ciliary body, and with better best-corrected visual acuity (BCVA). A subgroup of 39% of the patients reported severe disability affecting eye-related tasks. Thirty-three per cent were highly concerned about various aspects of their future health. Patients who underwent enucleation reported lower eye-related QoL and described problems related to body image in response to the open question.
CONCLUSION: General QoL of UM patients is only slightly affected by their malignancy. However, body image and psychosocial adjustment are major issues involved in evaluating QoL. Continuous long-term psychosocial treatment is needed from the time of diagnosis in a subgroup of patients suffering from eye-related disabilities.
© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  EORTC QLQ-OPT30; long-term survivors; quality of life; uveal melanoma

Mesh:

Year:  2018        PMID: 29369538     DOI: 10.1111/aos.13655

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  7 in total

Review 1.  Predictors of emotional distress in uveal melanoma survivors: a systematic review.

Authors:  Cari Davies; Stephen Lloyd Brown; Peter Fisher; Laura Hope-Stone; Debra Fisher; Andrew Morgan; Mary Gemma Cherry
Journal:  Eye (Lond)       Date:  2022-08-08       Impact factor: 4.456

2.  Screening for Predictive Parameters Requiring Psycho-Oncological Intervention via the National Comprehensive Cancer Network Distress Thermometer in the Follow-Up of Uveal Melanoma Patients.

Authors:  Annemarie Klingenstein; Christina Samel; Aylin Garip-Kuebler; Siegfried G Priglinger; Paul I Foerster
Journal:  Clin Ophthalmol       Date:  2020-11-09

3.  Quality of Life in Uveal Melanoma Patients in Ireland: A Single-Centre Survey.

Authors:  Olya Scannell; Valerie O'Neill; Mary Dunne; Caroline Baily; Amira Salih; Moya Cunningham; Noel Horgan
Journal:  Ocul Oncol Pathol       Date:  2019-08-22

4.  Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis.

Authors:  Christopher A Barker; Anna Kozlova; Alexander N Shoushtari; Jennifer L Hay; Jasmine H Francis; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2019-09-27

5.  Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study.

Authors:  Marietta Lieb; Sefik Tagay; Anja Breidenstein; Tobias Hepp; Claudia H D Le Guin; Jennifer Scheel; Dietmar R Lohmann; Norbert Bornfeld; Martin Teufel; Yesim Erim
Journal:  BMC Psychol       Date:  2020-01-31

6.  MiR-9-5p Inhibits the Proliferation, Migration and Invasion of Choroidal Melanoma by Targeting BRAF.

Authors:  Manman Ying; Hao Feng; Xiaonan Zhang; Ran Liu; Hong Ning
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

7.  Prognostic and Functional Analysis of NPY6R in Uveal Melanoma Using Bioinformatics.

Authors:  ShiMin Mei; Yue Li; Xueran Kang
Journal:  Dis Markers       Date:  2022-04-08       Impact factor: 3.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.